Tafamidis for the treatment of transthyretin amyloidosis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 387(10038), 2641–2654 (2016).
  Medline CASGoogle Scholar
• 2 Ando Y, Coelho T, Berk JL et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J. Rare Dis. 8(1), 1–18 (2013).
  MedlineGoogle Scholar
• 3 Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379(11), 1007–1016 (2018). •• Landmark randomized controlled trial investigating the effect of tafamidis on survival and CV hospitalizations in transthyretin (TTR) related cardiomyopathy.
  Medline CASGoogle Scholar
• 4 Dickson PW, Aldred AR, Marley PD, Tu GF, Howlett GJ, Schreiber G. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem. Biophys. Res. Commun. 127(3), 890–895 (1985).
  Medline CASGoogle Scholar
• 5 Foss TR, Wiseman RL, Kelly JW. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 44(47), 15525–15533 (2005).
  Medline CASGoogle Scholar
• 6 Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36(4), 411–423 (2007).
  Medline CASGoogle Scholar
• 7 Bartalena L, Robbins J. Thyroid hormone transport proteins. Clin. Lab. Med. 13(3), 583–598 (1993).
  Medline CASGoogle Scholar
• 8 Schreiber G, Southwell BR, Richardson SJ. Hormone delivery systems to the brain – transthyretin. Exp. Clin. Endocrinol. Diabetes 103(2), 75–80 (1995).
  Medline CASGoogle Scholar
• 9 Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38(12), 911–921 (2005).
  Medline CASGoogle Scholar
• 10 Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43(23), 7365–7381 (2004).
  Medline CASGoogle Scholar
• 11 Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl Acad. Sci. USA 101(9), 2817–2822 (2004).
  Medline CASGoogle Scholar
• 12 Coelho T, Maia LF, Martins da Silva A et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8), 785–792 (2012). • Randomized controlled trial of tafamidis for the treatment of TTR-related neuropathy in patients with V30M mutation.
  Medline CASGoogle Scholar
• 13 Hou X, Aguilar M-I, Small DH. Transthyretin and familial amyloidotic polyneuropathy. FEBS J. 274(7), 1637–1650 (2007).
  Medline CASGoogle Scholar
• 14 Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc. Natl Acad. Sci. USA 99(Suppl. 4), 16427–16432 (2002).
  Medline CASGoogle Scholar
• 15 Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52(11), 1913–1926 (2013).
  Medline CASGoogle Scholar
• 16 Mutations in hereditary amyloidosis. Mutations in transthyretin gene (TTR). http://amyloidosismutations.com/mut-attr.php
  Google Scholar
• 17 Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35(1), 116–118 (2007).
  Medline CASGoogle Scholar
• 18 Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 58(7), 1001–1007 (2002).
  Medline CASGoogle Scholar
• 19 Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranløv PJ. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J. Intern. Med. 254(3), 225–235 (2003).
  Medline CASGoogle Scholar
• 20 Rapezzi C, Quarta CC, Obici L et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur. Heart J. 34(7), 520–528 (2013).
  Medline CASGoogle Scholar
• 21 Quarta CC, Buxbaum JN, Shah AM et al. The amyloidogenic V122I transthyretin variant in elderly Black Americans. N. Engl. J. Med. 372(1), 21–29 (2015).
  MedlineGoogle Scholar
• 22 Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch. Neurol. 62(7), 1057 (2005).
  MedlineGoogle Scholar
• 23 Sattianayagam PT, Hahn AF, Whelan CJ et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur. Heart J. 33(9), 1120–1127 (2012).
  Medline CASGoogle Scholar
• 24 Koike H, Misu K, Ikeda S et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch. Neurol. 59(11), 1771–1776 (2002).
  MedlineGoogle Scholar
• 25 Koike H, Tanaka F, Hashimoto R et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from nonendemic areas. J. Neurol. Neurosurg. Psychiatry 83(2), 152–158 (2012).
  MedlineGoogle Scholar
• 26 Rapezzi C, Riva L, Quarta CC et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15(1), 40–48 (2008).
  Medline CASGoogle Scholar
• 27 Suhr OB, Lundgren E, Westermark P. One mutation two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J. Intern. Med. 281(4), 337–347 (2017).
  Medline CASGoogle Scholar
• 28 González-López E, Gagliardi C, Dominguez F et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur. Heart J. 38(24), 1895–1904 (2017).
  Medline CASGoogle Scholar
• 29 Connors LH, Sam F, Skinner M et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133(3), 282–290 (2016).
  Medline CASGoogle Scholar
• 30 Martinez-Naharro A, Treibel T, Abdel-Gadir A et al. Magnetic resonance in transthyretin cardiac amyloidosis. J. Am. Coll. Cardiol. 70(4), 466–477 (2017).
  Google Scholar
• 31 Quarta CC, Solomon SD, Uraizee I et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 129(18), 1840–1849 (2014).
  MedlineGoogle Scholar
• 32 Rapezzi C, Quarta CC, Riva L et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat. Rev. Cardiol. 7(7), 398–408 (2010).
  Medline CASGoogle Scholar
• 33 de Carvalho M, Conceição I, Bentes C, Luís MLS. Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 9(2), 126–133 (2002).
  MedlineGoogle Scholar
• 34 Okamoto S, Wixner J, Obayashi K et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transplant. 15(10), 1229–1235 (2009).
  MedlineGoogle Scholar
• 35 Saelices L, Chung K, Lee JH et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc. Natl Acad. Sci. USA 115(29), E6741–E6750 (2018).
  Medline CASGoogle Scholar
• 36 Stangou AJ, Hawkins PN, Heaton ND et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 66(2), 229–233 (1998).
  Medline CASGoogle Scholar
• 37 Coelho T, Chorão R, Sousa A, Alves I, Torres MF, Saraiva MJM. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscul. Disord. 6, S20 (1996).
  Google Scholar
• 38 Longo Alves I, Hays MT, Saraiva MJM. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur. J. Biochem. 249(3), 662–668 (1997).
  Medline CASGoogle Scholar
• 39 Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin arnyloid disease by changing protein misfolding energetics. Science 299(5607), 713–716 (2003).
  MedlineGoogle Scholar
• 40 White JT, Kelly JW. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl Acad. Sci. USA 98(23), 13019–13024 (2001).
  Medline CASGoogle Scholar
• 41 Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13(4), 236–249 (2006).
  Medline CASGoogle Scholar
• 42 Bulawa CE, Connelly S, Devit M et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA 109(24), 9629–9634 (2012). • In vitro and ex vivo evidence of the effect of tafamidis on TTR.
  Medline CASGoogle Scholar
• 43 European Medicines Agency summary of the European public assessment report (EPAR) for Vyndaqel. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002294/human_med_001498.jsp&mid=WC0b01ac058001d124
  Google Scholar
• 44 Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J. Intern. Med. 235(5), 479–485 (1994).
  Medline CASGoogle Scholar
• 45 Coelho T, Maia LF, Da Silva AM et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J. Neurol. 260(11), 2802–2814 (2013).
  Medline CASGoogle Scholar
• 46 Merlini G, Planté-Bordeneuve V, Judge DP et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J. Cardiovasc. Transl. Res. 6(6), 1011–1020 (2013).
  MedlineGoogle Scholar
• 47 Barroso FA, Judge DP, Ebede B et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24(3), 194–204 (2017).
  Medline CASGoogle Scholar
• 48 Yukio A, Yoshiki S, Konen O et al. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: a Phase III, open-label study. J. Neurol. Sci. 362, 266–271 (2016).
  Medline CASGoogle Scholar
• 49 Conceição I, Miranda B, Castro J, de Carvalho M. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients. Eur. J. Neurol. 25(11), 1320-e115 (2018).
  MedlineGoogle Scholar
• 50 Mundayat R, Stewart M, Alvir J et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol. Ther. 7, 87–101 (2018).
  MedlineGoogle Scholar
• 51 Maurer MS, Grogan DR, Judge DP et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ. Heart Fail. 8(3), 519–526 (2015).
  MedlineGoogle Scholar
• 52 Ruberg FL, Maurer MS, Judge DP et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am. Heart J. 164(2), 222.e1–228.e1 (2012).
  Google Scholar
• 53 Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH. Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy. Clin. Med. Insights Cardiol. 11, 1–4 (2017).
  CASGoogle Scholar
• 54 Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite end points in clinical trials based on clinical priorities. Eur. Heart J. 33(2), 176–182 (2012). • Clear explanation of a novel method to optimize the analysis of composite end points in clinical trials.
  MedlineGoogle Scholar
• 55 Gillmore JD, Maurer MS, Falk RH et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24), 2404–2412 (2016). •• Multicenter study that provided the evidence basis for reaching a definitive diagnosis of TTR-related cardiac amyloidosis noninvasively.
  Medline CASGoogle Scholar
• 56 Longhi S, Lorenzini M, Gagliardi C et al. Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc. Imaging 9(3), 325–327 (2016).
  MedlineGoogle Scholar
• 57 Castano A, Narotsky DL, Hamid N et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur. Heart J. 38(38), 2879–2887 (2017).
  MedlineGoogle Scholar
• 58 Cavalcante JL, Rijal S, Abdelkarim I et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J. Cardiovasc. Magn. Reson. 19(1), 98 (2017).
  MedlineGoogle Scholar
• 59 Adams D, Gonzalez-Duarte A, O'Riordan WD et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379(1), 11–21 (2018).
  Medline CASGoogle Scholar
• 60 Benson MD, Waddington-Cruz M, Berk JL et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379(1), 22–31 (2018).
  Medline CASGoogle Scholar
• 61 Solomon SD, Adams D, Kristen A et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO Study. Circulation 139(4), 431–443 (2018).
  Google Scholar